Amgen Inc (AMGN) 122.01 $AMGN
Final Glance: Biotechnology companies
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Midday Glance: Biotechnology companies
AP - Wed Jul 23, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
PR Newswire - Mon Jul 21, 9:00AM CDT
Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages this proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has over other statin add-on therapies are due to its highly efficacious LDL-C lowering capabilities and the potential to reduce the risk of cardiovascular disease.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Colorado BioScience Association Recognizes Amgen Foundation's $25,000 Investment in STEM Education in Colorado's Classrooms
Business Wire - Mon Jul 21, 8:00AM CDT
The Colorado BioScience Association (CBSA) is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute (CBSI) in support of the Research Experience for Teachers (RET) program, in addition to funds provided by others including The Anschutz Foundation. The announcement is made by CBSA/CBSI President & CEO April Giles, who says, "We are honored to receive these grants for our RET program and know it will make a positive impact in Colorado's science classrooms."
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
Final Glance: Biotechnology companies
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Midday Glance: Biotechnology companies
AP - Wed Jul 23, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
PR Newswire - Mon Jul 21, 9:00AM CDT
Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages this proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has over other statin add-on therapies are due to its highly efficacious LDL-C lowering capabilities and the potential to reduce the risk of cardiovascular disease.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Colorado BioScience Association Recognizes Amgen Foundation's $25,000 Investment in STEM Education in Colorado's Classrooms
Business Wire - Mon Jul 21, 8:00AM CDT
The Colorado BioScience Association (CBSA) is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute (CBSI) in support of the Research Experience for Teachers (RET) program, in addition to funds provided by others including The Anschutz Foundation. The announcement is made by CBSA/CBSI President & CEO April Giles, who says, "We are honored to receive these grants for our RET program and know it will make a positive impact in Colorado's science classrooms."
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
